Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Department of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St, MSC606, Charleston, SC, 29425, USA.
Metab Brain Dis. 2020 Feb;35(2):255-261. doi: 10.1007/s11011-019-00521-1. Epub 2019 Dec 18.
This study examines the cytokine/chemokine profile of a 62-year-old African American male with progressive multiple sclerosis (MS). MRI images of the MS patient demonstrated generalized white matter involvement with multiple lesions in the periventricular area. A 42-plex Discovery Assay® (Eve Technologies) of the patient's plasma and peripheral blood mononuclear cells (PBMCs) supernatant or PBMC-derived T cell supernatant samples from two separate clinic visits revealed vastly differing cytokine/chemokine levels. In addition, certain cytokine/chemokine profiles had notable differences when compared to the larger patient group or patients' PBMCs treated with a calpain inhibitor in vitro. Interestingly, large numbers of cytokines/chemokines and growth factors in MS PBMCs are modulated by calpain inhibition, suggesting the clinical significance of these findings in designing better therapeutics against progressive MS.
本研究检测了一位 62 岁非裔美国男性进行性多发性硬化症（MS）的细胞因子/趋化因子谱。MS 患者的 MRI 图像显示弥漫性脑白质受累，伴有脑室周围区域的多个病变。使用 Eve Technologies 的 42 plex Discovery Assay®（Eve 技术）对该患者的血浆和外周血单核细胞（PBMC）上清液或来自两次不同就诊的 PBMC 来源 T 细胞上清液样本进行分析，揭示了细胞因子/趋化因子水平的巨大差异。此外，与更大的患者群体或体外用钙蛋白酶抑制剂处理的患者 PBMCs 相比，某些细胞因子/趋化因子谱存在显著差异。有趣的是，钙蛋白酶抑制可调节 MS PBMC 中的大量细胞因子/趋化因子和生长因子，这表明这些发现对于设计针对进行性 MS 的更好治疗方法具有临床意义。
